JP5875597B2 - ヒト万能性幹細胞の成長を阻害する薬剤および方法 - Google Patents

ヒト万能性幹細胞の成長を阻害する薬剤および方法 Download PDF

Info

Publication number
JP5875597B2
JP5875597B2 JP2013543140A JP2013543140A JP5875597B2 JP 5875597 B2 JP5875597 B2 JP 5875597B2 JP 2013543140 A JP2013543140 A JP 2013543140A JP 2013543140 A JP2013543140 A JP 2013543140A JP 5875597 B2 JP5875597 B2 JP 5875597B2
Authority
JP
Japan
Prior art keywords
cells
cell
differentiation
day
culture
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2013543140A
Other languages
English (en)
Japanese (ja)
Other versions
JP2014501518A5 (enExample
JP2014501518A (ja
Inventor
シュルツ,トーマス
ロビンス,アラン
Original Assignee
ヴィアサイト,インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ヴィアサイト,インコーポレイテッド filed Critical ヴィアサイト,インコーポレイテッド
Publication of JP2014501518A publication Critical patent/JP2014501518A/ja
Publication of JP2014501518A5 publication Critical patent/JP2014501518A5/ja
Application granted granted Critical
Publication of JP5875597B2 publication Critical patent/JP5875597B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06Animal cells or tissues; Human cells or tissues
    • C12N5/0602Vertebrate cells
    • C12N5/0603Embryonic cells ; Embryoid bodies
    • C12N5/0606Pluripotent embryonic cells, e.g. embryonic stem cells [ES]
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06Animal cells or tissues; Human cells or tissues
    • C12N5/0602Vertebrate cells
    • C12N5/0696Artificially induced pluripotent stem cells, e.g. iPS
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/5073Stem cells
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00Active agents used in cell culture processes, e.g. differentation
    • C12N2501/999Small molecules not provided for elsewhere
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2503/00Use of cells in diagnostics
    • C12N2503/02Drug screening

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Cell Biology (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Gynecology & Obstetrics (AREA)
  • Reproductive Health (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Food Science & Technology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Toxicology (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Transplantation (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Investigating Or Analyzing Materials By The Use Of Electric Means (AREA)
JP2013543140A 2010-12-08 2010-12-08 ヒト万能性幹細胞の成長を阻害する薬剤および方法 Expired - Fee Related JP5875597B2 (ja)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/US2010/059586 WO2012078153A1 (en) 2010-12-08 2010-12-08 Agents and methods for inhibiting human pluripotent stem cell growth

Publications (3)

Publication Number Publication Date
JP2014501518A JP2014501518A (ja) 2014-01-23
JP2014501518A5 JP2014501518A5 (enExample) 2014-03-13
JP5875597B2 true JP5875597B2 (ja) 2016-03-02

Family

ID=46207417

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2013543140A Expired - Fee Related JP5875597B2 (ja) 2010-12-08 2010-12-08 ヒト万能性幹細胞の成長を阻害する薬剤および方法

Country Status (8)

Country Link
US (2) US9365830B2 (enExample)
EP (1) EP2649177B1 (enExample)
JP (1) JP5875597B2 (enExample)
CN (1) CN103354835B (enExample)
AU (1) AU2010365057B2 (enExample)
CA (1) CA2820419A1 (enExample)
ES (1) ES2690663T3 (enExample)
WO (1) WO2012078153A1 (enExample)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103124788B (zh) 2010-05-21 2016-01-13 梅里麦克制药股份有限公司 双特异性融合蛋白
EP2723852B1 (en) 2011-06-21 2021-11-17 Novo Nordisk A/S Efficient induction of definitive endoderm from pluripotent stem cells
EP2980207B1 (en) * 2013-03-25 2018-12-05 Foundation for Biomedical Research and Innovation at Kobe Cell sorting method
EP3006558B1 (en) * 2013-05-30 2020-05-13 Ajinomoto Co., Inc. Medium for culturing stem cells
CA2922079C (en) 2013-08-23 2022-07-05 Sumitomo Chemical Company, Limited Method for producing retinal tissue and retina-related cells
EP3097186B1 (en) * 2014-01-21 2019-05-08 The Medical College of Wisconsin, Inc. Methods for selective inhibition of pluripotent stem cells
WO2015151307A1 (ja) * 2014-03-31 2015-10-08 味の素株式会社 幹細胞用培地
WO2017025061A1 (en) * 2015-08-13 2017-02-16 Peking University Induced extended pluripotent stem cells, methods of making and using
CN108367048B (zh) 2015-10-02 2022-08-12 银溪制药股份有限公司 用于组织修复的双特异性治疗性蛋白质
WO2017123806A1 (en) 2016-01-12 2017-07-20 Cedars-Sinai Medical Center A method of non destructive monitoring of biological processes in microfluidic tissue culture systems
US11913022B2 (en) * 2017-01-25 2024-02-27 Cedars-Sinai Medical Center In vitro induction of mammary-like differentiation from human pluripotent stem cells
WO2018139600A1 (ja) * 2017-01-27 2018-08-02 株式会社カネカ 内胚葉系細胞集団、及び多能性細胞から三胚葉のいずれかの細胞集団を製造する方法
AU2018231210A1 (en) * 2017-03-07 2019-09-19 Platelet Biogenesis, Inc. Recirculating bioreactor
US11767513B2 (en) 2017-03-14 2023-09-26 Cedars-Sinai Medical Center Neuromuscular junction
US10767164B2 (en) 2017-03-30 2020-09-08 The Research Foundation For The State University Of New York Microenvironments for self-assembly of islet organoids from stem cells differentiation
JP7298844B2 (ja) 2017-06-05 2023-06-27 テルモ株式会社 細胞培養物の製造方法
US10391156B2 (en) 2017-07-12 2019-08-27 Viacyte, Inc. University donor cells and related methods
CN108570443A (zh) * 2017-12-05 2018-09-25 皓昇莱生物制药有限公司 一种用于培养尿液来源细胞的培养基
EP3768823B1 (en) 2018-03-23 2025-12-31 Cedars-Sinai Medical Center METHODS FOR USING CELLS FROM PANCREATIC ISLETS
EP3778871A4 (en) * 2018-03-28 2021-07-14 Osaka University METHOD FOR PRODUCING TEAR TISSUE FROM STEM CELLS
JP7464532B2 (ja) 2018-04-06 2024-04-09 シーダーズ-サイナイ メディカル センター マイクロ流体チップ上のヒト多能性幹細胞由来の神経変性疾患モデル
US11981918B2 (en) 2018-04-06 2024-05-14 Cedars-Sinai Medical Center Differentiation technique to generate dopaminergic neurons from induced pluripotent stem cells
CN110684714B (zh) * 2018-07-05 2023-05-09 广东博溪生物科技有限公司 一种屏障功能弱化模型的构建方法
BR112021000996A2 (pt) 2018-07-19 2021-04-20 Platelet Biogenesis, Inc. biorreator de recirculação empilhado
US10724052B2 (en) 2018-09-07 2020-07-28 Crispr Therapeutics Ag Universal donor cells
AU2019343003B2 (en) * 2018-09-19 2025-07-17 Orizuru Therapeutics, Inc. Insulin-producing cells
JP7781522B2 (ja) 2018-09-27 2025-12-08 国立大学法人大阪大学 多能性幹細胞由来細胞のシート化方法
WO2020130077A1 (ja) * 2018-12-21 2020-06-25 国立大学法人北海道大学 多能性幹細胞を除去するための組成物、及び多能性幹細胞の除去方法
CN110373375A (zh) * 2019-03-19 2019-10-25 杭州原生生物科技有限公司 一种制备纤维细胞作为细胞培养基的方法和用途
MX2022002783A (es) 2019-09-05 2022-04-06 Crispr Therapeutics Ag Celulas donantes universales.
PH12022550542A1 (en) 2019-09-05 2023-03-20 Crispr Therapeutics Ag Universal donor cells
MX2023001914A (es) 2020-08-15 2023-03-13 Regeneron Pharma Tratamiento de la obesidad en sujetos que tienen variantes de moleculas de acido nucleico que codifican el receptor de calcitonina (calcr).
US11578309B2 (en) 2020-12-31 2023-02-14 Crispr Therapeutics Ag Universal donor cells
TW202523836A (zh) * 2023-12-12 2025-06-16 佛教慈濟醫療財團法人 選擇性去除未分化多潛能幹細胞的方法

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5861483A (en) * 1996-04-03 1999-01-19 Pro-Neuron, Inc. Inhibitor of stem cell proliferation and uses thereof
IL142748A0 (en) 1998-11-09 2002-03-10 Univ Monash Embryonic stem cells
US8597947B2 (en) * 2004-12-29 2013-12-03 Hadasit Medical Research Services & Development Limited Undifferentiated stem cell culture systems
US20080070303A1 (en) * 2005-11-21 2008-03-20 West Michael D Methods to accelerate the isolation of novel cell strains from pluripotent stem cells and cells obtained thereby
US20120295346A1 (en) * 2009-07-22 2012-11-22 Tufts University Methods and compositions for modulating membrane potential to influence cell behavior

Also Published As

Publication number Publication date
AU2010365057B2 (en) 2016-12-22
EP2649177A1 (en) 2013-10-16
EP2649177B1 (en) 2018-09-05
US20130280802A1 (en) 2013-10-24
CN103354835A (zh) 2013-10-16
CA2820419A1 (en) 2012-06-14
ES2690663T3 (es) 2018-11-21
EP2649177A4 (en) 2014-04-23
JP2014501518A (ja) 2014-01-23
WO2012078153A1 (en) 2012-06-14
CN103354835B (zh) 2016-03-02
AU2010365057A1 (en) 2013-06-20
US20160281058A1 (en) 2016-09-29
US9365830B2 (en) 2016-06-14

Similar Documents

Publication Publication Date Title
JP5875597B2 (ja) ヒト万能性幹細胞の成長を阻害する薬剤および方法
JP7490035B2 (ja) 多能性幹細胞の膵臓内胚葉細胞(PEC)および内分泌細胞へのin vitro分化
Xu et al. Activin, BMP and FGF pathways cooperate to promote endoderm and pancreatic lineage cell differentiation from human embryonic stem cells
US8445273B2 (en) Stem cell aggregate suspension compositions and methods of differentiation thereof
CN102361970B (zh) 干细胞聚集体悬浮组合物及其分化方法
KR102180779B1 (ko) 규모조정가능한 영장류 만능 줄기 세포 응집체 현탁 배양물 및 그의 분화
JP6810103B2 (ja) 幹細胞集合体懸濁液組成物、その分化方法
JP2021058192A (ja) 幹細胞集合体懸濁液組成物、その分化方法
JP2014036660A (ja) 幹細胞集合体懸濁液組成物、その分化方法

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20131204

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20131204

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20131205

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20150224

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20150430

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20150821

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20151222

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20160119

R150 Certificate of patent or registration of utility model

Ref document number: 5875597

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

LAPS Cancellation because of no payment of annual fees